To include your compound in the COVID-19 Resource Center, submit it here.

Stelara ustekinumab: Phase IIb data

The double-blind Phase IIb CERTIFI trial in 526 patients with moderately to severely active CD who had previously failed or were intolerant to >=1 tumor necrosis factor (TNF) antagonist showed that

Read the full 319 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE